Solid Tumor Oncology
Oxford Biotherapeutics Limited focuses on recurrent and metastatic solid tumors with CD205-positive disease expression, including gastric cancer, non-small cell lung cancer, endometrial cancer, and ovarian cancer.
- CD205-positive tumor types
- Metastatic cancer
- Recurrent solid malignancies
The sponsor’s clinical activity is centered on cancers with advanced disease burden across multiple tumor origins.
Immuno-Oncology
The research portfolio includes immune-based cancer therapy in combination settings, with interest in balstilimab alongside targeted treatment for advanced tumors.
- Checkpoint-based therapy
- Combination oncology treatment
- Immune modulation
This area reflects a therapeutic focus on integrating immune mechanisms into treatment strategies for difficult-to-treat cancers.
Targeted Antibody Therapeutics
Oxford Biotherapeutics Limited is engaged in development of OBT076, a therapy directed toward CD205-expressing tumors, highlighting interest in antibody-based oncology and precision targeting.
- Antibody therapy
- Target antigen CD205
- Precision cancer targeting
The sponsor’s work is aligned with therapies designed to selectively address tumor-associated markers in advanced malignancies.
Advanced Clinical Oncology Development
The sponsor’s clinical research spans multinational oncology studies across several active countries and collaborating sites, supporting evaluation in patients with limited treatment options.
- Multicountry cancer trials
- Advanced solid tumor populations
- Specialist oncology sites
Its research activity is concentrated in the clinical development of therapies for late-stage cancer care.
